Analyst Consensus ?
ConsensusHold29 ratings
Bullish1655.2%
Neutral724.1%
Bearish620.7%
UBS Group AG · UBS · FY2026 Q2 · Calendar Q3 2026
UBS Reports Strong Q2 as Integration Nears Completion
The quarter provides evidence that strong wealth inflows, investment-banking activity, cost synergies and Credit Suisse integration progress are supporting UBS's profitability. The thesis remains conditional on sustained market activity, successful integration, regulatory clarity and continued execution of capital and cost plans.
Reported Before market openNYSEFinancial Services
$146.01B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.87
Consensus $0.90
EPS surprise
-3.3%
Reported versus consensus
Reported revenue
$13.35B
Consensus $13.40B
Revenue surprise
-0.4%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-0.4%
Event window
SPY move
-1.5%
Same window
Abnormal move
+1.1%
Stock minus SPY
Volume
1.9×
Versus trailing sessions
Subsequent drift
+5.3%
Up to 20 sessions
UBSSPY benchmark
Ask FN2 about UBS FY2026 Q2
Transcript, numbers and history already loaded
Why did UBS fall 0.4% after missing EPS estimates in FY2026 Q2?What changed in UBS's guidance and outlook in FY2026 Q2?Give me the bull and bear case for UBS after FY2026 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, UBS reported stronger current-quarter profitability, record invested assets and $36 billion of wealth-management net new assets. Credit Suisse integration advanced to 90% legacy-application decommissioning, while the company introduced a $3 billion buyback program through Q2 2027 and highlighted continued technology investment.
Guidance delta
Maintained. Management reaffirmed the outlook, including 10% growth in Global Wealth Management net interest income and 2026 profitability and cost/income targets.
Key takeaways
- Pretax profit rose 45% year over year to $3.9 billion, with return on CET1 around 16.4%.
- Global Wealth Management recorded $36 billion of net new assets; invested assets reached a record $7.3 trillion.
- Investment Banking revenue reached a record $3.7 billion, with equity trading up 53%.
- Credit Suisse integration is nearing completion, with 90% of legacy applications decommissioned and $12.6 billion of cost synergies realized.
- UBS announced a $3 billion share repurchase program through Q2 2027.
Management priorities
- Complete Credit Suisse integration, including remaining legacy application migration, by year-end.
- Execute the $3 billion share repurchase program, including at least $1 billion over the next three months.
- Accelerate investment in AI, digital assets and technology infrastructure.
- Expand high-net-worth adviser capacity and digital platforms in Asia, particularly Hong Kong.
- Continue cost reduction toward the $13.5 billion annual synergy target.
Follow UBS with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$47.69Current
$19.24Low
$23.57Average
$34High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Barclays | Equal Weight | Underweight | Upgrade | Apr 20, 2026 |
| B of A Securities | Buy | Neutral | Upgrade | Dec 16, 2025 |
| Jefferies | Buy | Hold | Upgrade | Jun 3, 2025 |
| Exane BNP Paribas | Outperform | Neutral | Upgrade | Jan 3, 2025 |
| Citigroup | Neutral | Buy | Downgrade | Apr 23, 2024 |
| Morgan Stanley | Overweight | Equal Weight | Upgrade | Mar 8, 2024 |
| RBC Capital | Outperform | Sector Perform | Upgrade | Oct 16, 2023 |
| Oddo Securities | Underperform | Neutral | Downgrade | Mar 20, 2023 |
| Deutsche Bank | Buy | Hold | Upgrade | May 19, 2021 |
| Berenberg | Buy | Hold | Upgrade | Jan 15, 2021 |
| Kepler Cheuvreux | Buy | Hold | Upgrade | Sep 10, 2019 |
| DZ Bank | Sell | Hold | Downgrade | Aug 21, 2019 |
| Societe Generale | Sell | Sell | Maintain | Jul 24, 2019 |
| Bank of America | Buy | Neutral | Upgrade | Nov 10, 2017 |
| JP Morgan | Neutral | Underweight | Upgrade | Dec 12, 2016 |
| Keefe, Bruyette & Woods | Outperform | Underperform | Upgrade | Nov 10, 2016 |
| Keefe Bruyette & Woods | Outperform | Underperform | Upgrade | Nov 10, 2016 |
| Credit Suisse | Neutral | Neutral | Maintain | Sep 19, 2016 |
| Bernstein | Underperform | Underperform | Maintain | Jul 12, 2016 |
| UBS | Sell | Sell | Maintain | Feb 17, 2016 |
| J. Safra Sarasin | Neutral | Buy | Downgrade | Feb 2, 2016 |
| Goldman Sachs | Neutral | Buy | Downgrade | Sep 15, 2015 |
| Mediobanca Securities | Outperform | Outperform | Maintain | Jun 15, 2015 |
| Rafferty Capital | Buy | Hold | Upgrade | May 6, 2014 |
| Rafferty | Buy | Hold | Upgrade | May 6, 2014 |
| MainFirst Bank AG | Outperform | Market Perform | Upgrade | Nov 5, 2013 |
| MainFirst | Outperform | Market Perform | Upgrade | Nov 5, 2013 |
| Bankhaus Lampe | Sell | Hold | Downgrade | Jun 20, 2013 |
| Rochdale Securities | Neutral | Buy | Downgrade | Aug 1, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $47.69. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Bank of America Securities | Antonio Reale | $34 | $30.3 | -28.7% | Sep 19, 2024 |
| Deutsche Bank | Benjamin Goy | $24.59 | $20.37 | -48.4% | Feb 3, 2022 |
| Berenberg Bank | Eoin Mullany | $23.52 | $20.53 | -50.7% | Feb 2, 2022 |
| Barclays | Amit Goel | $21.38 | $20.4 | -55.2% | Feb 1, 2022 |
| Morgan Stanley | Magdalena Stoklosa | $22.45 | $17.15 | -52.9% | Nov 29, 2021 |
| DZ BANK AG | Markus Mischker | $19.24 | $17.96 | -59.6% | Oct 26, 2021 |
| Societe Generale | Andrew T Lim | $19.78 | $16.14 | -58.5% | Sep 27, 2021 |
Track every rating change on UBS the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationUBS Group AG, a financial services giant headquartered in Zurich, Switzerland, since its founding in 1862 (and known as UBS AG until its name change in December 2014), delivers a comprehensive range of financial advice and solutions to a global clientele of private individuals, institutions, and corporations. The firm structures its operations across four primary business segments: The Global Wealth Management division caters specifically to affluent and ultra-high-net-worth clients. It provides sophisticated investment guidance, various lending products, including mortgages and securities-based loans, and extensive planning services encompassing estate and wealth management, philanthropy, corporate and banking services, and family advisory. Through its Personal & Corporate Banking arm, UBS supports individual clients with essential banking services like deposits, cards, and digital platforms, alongside financing, investment opportunities, and retirement solutions.…
Historical context
All UBS earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| CBOE Cboe Global Markets, Inc. | FY2026 Q3 · Calendar Q4 2026 | +5.8% | +6.8% | Cboe posts strong Q3 as options growth and new products advance |
| NWG NatWest Group plc | FY2026 Q3 · Calendar Q4 2026 | +2.0% | -9.0% | NatWest maintains guidance as Q3 growth and capital remain strong |
| ERIE Erie Indemnity Company | FY2026 Q3 · Calendar Q4 2026 | +2.1% | +5.3% | Erie pairs resilient demand initiatives with thin underwriting margins |
| COIN Coinbase Global, Inc. | FY2026 Q3 · Calendar Q4 2026 | +1189.2% | -10.6% | Coinbase offsets lower spot trading with prediction markets and AI agents |
| TPG TPG Inc. | FY2026 Q3 · Calendar Q4 2026 | +4.3% | +7.5% | TPG raises FRE margin outlook as capital formation accelerates |
| AJG Arthur J. Gallagher & Co. | FY2026 Q3 · Calendar Q4 2026 | +0.3% | +2.9% | AJG: Q3 growth and AssuredPartners synergies support outlook |
Latest beats and misses
Who reports nextBeat on EPS
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- AZNFY2026 Q3 · October 30, 2026+7.3% EPS+7.0% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the UBS recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-07-29T18:06:20.705734+00:00
- FN2 earnings calendar · 2026-09-03T01:23:14.877038+00:00
- Polygon adjusted daily market bars · 2026-10-31T17:30:40.912863+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-31T17:30:40.910022+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-31. For educational purposes only; not investment advice.